Japan’s ruling coalition sustained a crushing blow in the Lower House election last month, only managing to win 215 seats,…
HOME > REGULATORY
REGULATORY
- Add Risk of Interstitial Pneumonia to Eliquis Package Insert: MHLW
February 18, 2015
- Abe Calls for Shrewd Strategies for Pharmas, Industry Consolidation as Necessary
February 18, 2015
- LDP Pharma Policy Study Group on Alert for 3 Consecutive Years of Drug Price Cuts
February 17, 2015
- MHLW Approves 309 Generic Products Ahead of June Listing; 32 Companies Obtain Approval for Plavix Generics Including AGs
February 17, 2015
- Panel Approves 43 More Diseases as Designated Intractable Diseases
February 17, 2015
- Gilead Told to Improve Biz Practice in Japan over Delayed ADR Reporting
February 16, 2015
- Health Minister to Kick Off Roundtable for Healthcare Policy for 2035 This Month
February 16, 2015
- PAFSC’s Second Committee to Discuss Celgene’s Multiple Myeloma Treatment Pomalidomide on Feb. 26
February 13, 2015
- PMDA Plans Manufacturing Inspections for 2 Regenerative Medicine Products This Year
February 12, 2015
- MHLW Pursuing Quick Approval of Japan-OK’ed Drugs in Emerging Markets
February 10, 2015
- Health Minister Says to Mull Revising Generic Share Target
February 10, 2015
- National Cancer Center Announces Guidelines for Clinical Trial Monitoring and Auditing
February 10, 2015
- Editor’s Pick: Five Healthcare News Headlines for Jan. 26 - Feb. 8
February 9, 2015
- PAFSC 1st Committee to Discuss Actelion’s PAH Treatment on Feb. 20
February 9, 2015
- Panel OKs Intractable Disease Designation of Muscular Dystrophy
February 6, 2015
- NHI Price System that Would Undermine Wholesalers’ Stable Supply Ability Unacceptable: HIB Director-General
February 6, 2015
- GSK Ordered to Issue Blue Letter on Lamictal
February 5, 2015
- MHLW Plans Business Suspension Order for Novartis
February 5, 2015
- R&D Tax Credit Overhaul Likely in FY2017, but In a Way to Spur Investments: LDP’s Goto
February 4, 2015
- Action to Be Taken against Novartis “Not Yet Decided”: Health Minister
February 4, 2015
ページ
For over two decades, Morunda has been at the forefront of interviewing and understanding leaders within Japan’s dynamic healthcare industry, particularly in pharmaceuticals and medical devices. What sets apart successful country managers in this competitive arena isn’t just their professional…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…